by
Werner SchmidtWerner Schmidt
An illuminating summary of our current understanding of the interactive role of dopamine and glutamate in psychiatric diseases and the therapeutic strategies and possibilities for future treatment. Among the new ideas presented are hypotheses on the role of dopamine and glutamate in aggression, the glutamate system in anxiety disorders, glutamate and neurodegeneration, and on the origin and progression of Parkinson’s disease. Additional chapters offer novel insights into a variety of psychiatric diseases, including ADHD, stress, aggression, addiction, schizophrenia, depression, social phobias, dementias, bulimia, and neurodegenerative diseases like Parkinson’s and Alzheimer’s diseases. Each chapter summarizes the prevalence and symptoms of the disease and explains the involvement of dopamine and/or glutamate systems using the newer molecular approaches such as transgenic knockout or knockin mice and recent brain imaging techniques.
$(document).on(‘googleAdsenseAdsLoaded’, function(){
var csaBodyClass = ‘pdpPage’ || document.getElementsByTagName(“BODY”)[0].className,
csaBreadcrumb = csaAdQuery = ”,
csaProductName = ‘Dopamine and Glutamate in Psychiatric Disorders / Edition 1’ || ‘Dopamine and Glutamate in Psychiatric Disorders / Edition 1’,
clientId = ‘partner-barnesandnoble_js’,
adWidth = ‘189px’;
if(csaBodyClass == ‘landingPage’) {
// If breadcrumb not in digitalData, then get from url
if(typeof s_setP != ‘undefined’) {
// Get breadcrumb from pageName property since it is the
// string format of breadcrumb, which is in an array
csaBreadcrumb = digitalData.page.pageInfo.pageName.replace(‘b’,”).trim();
} else {
var csaUrl = window.location.href,
slashBIndex = csaUrl.indexOf(‘/b/’)
underscoreIndex = csaUrl.indexOf(‘/_’);
csaBreadcrumb = csaUrl.slice(slashBIndex, underscoreIndex).replace(‘/b/’,”).trim();
}
}
// Double check the bodyClass from header-javascript variable
if(csaBodyClass.indexOf(‘searchResultsPage’) >= 0 || csaBodyClass == ‘landingPage searchResultsPage’) {
csaBodyClass = ‘searchResultsPage’;
}
switch (csaBodyClass) {
case ‘landingPage’:
var csaAdQuery = csaBreadcrumb;
break;
case ‘searchResultsPage’:
var csaAdQuery = ”;
break;
case ‘pdpPage’:
var csaAdQuery = csaProductName,
clientId = ‘partner-barnesandnoble-pdp’,
adWidth = ‘300px’;
break;
default:
break;
}
// Call google ads
if(csaAdQuery) {
var csaPageOptions = {
‘pubId’: clientId,
‘query’: csaAdQuery,
‘hl’: ‘en’,
‘adPage’: 1
};
var adblock1 = {
‘container’: ‘adcontainer1’,
‘width’: adWidth
};
_googCsa(‘ads’, csaPageOptions, adblock1);
setTimeout(function(){
if($(‘#adcontainer1 iframe’).length > 0) {
$(‘#adcontainer1 iframe’).attr(‘title’, ‘Advertising’);
}
}, 5000);
}
})
Product Details
- ISBN-13:
- 9781588293251
- Publisher:
- Springer-Verlag New York, LLC
- Publication date:
- 03/18/2005
- Edition description:
- 2005
- Pages:
- 600
- Product dimensions:
- 7.01(w) x 10.00(h) x 0.05(d)
Table of Contents
Part I. Dopamine
Dopamine Receptors
Kim A. Neve
Dopamine Receptor Alternative Splicing
Neil M. Richtand, Laurel M. Pritchard, and Lique M. Coolen
Part II. Glutamate
Glutamatergic Pathways: Their Relevance for Psychiatric Diseases
Yoland Smith
Glutamate Receptors: Ionotropic
Daniel T. Monaghan, Julia C. A. More, Bihua Feng, and David E. Jane
Metabotropic Glutamate Receptors
Krystyna Ossowska
Part III. Schizophrenia
Dopamine and Schizophrenia
Bart A. Ellenbroek
Glutamate and Schizophrenia and the N-Methyl-d-Aspartate Receptor Hypofunction Hypothesis
Stefan Bleich and Johannes Kornhuber
Role of Glycine in Schizophrenia
Beate D. Kretschmer
Part IV. Depression
Dopamine and Depression
Phil Skolnick
Glutamate and Depression
Joaquín Del Río and Diana Frechilla
Part V. Stress and Aggression
Dopamine, Glutamate, and Aggression
Klaus A. Miczek and Eric W. Fish
Part VI. Anxiety
Glutamatergic Systems and Anxiety
David N. Stephens
Part VII. Attention Deficit Hyperactivity Disorder
Dopamine and Glutamate in Attention Deficit Hyperactivity Disorder
James M. Swanson, Nora D. Volkow, Jeffrey Newcorn, B. J. Casey, Robert Moyzis, David K. Grandy, and Michael I. Posner
Part VIII. Addiction
Dopamine-Glutamate Interactions in Reward-Related Incentive Learning
Richard J. Beninger and Todor V. Gerdjikov
Sensitization and Relapse: Dopamine-Glutamate Interactions
David A. Baker and Peter W. Kalivas
Glutamatergic Neurotransmission in Sensitization
Thomas M. Tzschentke
Glutamatergic Mechanisms of Drug Relapse: Withdrawal and Conditioning Factors
Anton Y. Bespalov and Robert L. Balster
Part IX. Neurodegeneration
Dopamine and Neurodegeneration
Gabriele Gille and Peter Riederer
Glutamate and Neurodegeneration
Antonello Novelli, Marcos Pérez-Basterrechea, and Maria Teresa Fernández-Sánchez
Part X. Parkinson’s Disease
Presymptomatic and Symptomatic Stages of Intracerebral Inclusion Body Pathology in Idiopathic Parkinson’s Disease
Heiko Braak and Kelly Del Tredici
Dopamine and Glutamate in Parkinson’s Disease: Biochemistry, Clinical Aspects, and Treatment
Heinz Reichmann, Bernd Janetzky, and Peter Riederer
Dopamine and Glutamate in Motor and Cognitive Symptoms of Parkinson’s Disease
Werner J. Schmidt
Part XI. Huntington’s Disease
Dopamine and Glutamate in Huntington’s Disease
Carlos Cepeda, Marjorie A. Ariano, and Michael S. Levine
Part XII. Dementias
Dopaminergic and Glutamatergic Systems in Alzheimer’s Disease
Paul T. Francis
Index
Product Details
| ISBN-13: | 9781588293251 | |
| Publisher: | Springer-Verlag New York, LLC | |
| Publication date: | 03/18/2005 | |
| Edition description: | 2005 | |
| Pages: | 600 | |
| Product dimensions: | 7.01(w) x 10.00(h) x 0.05(d) |
Reviews
There are no reviews yet.